Inhibikase Therapeutics, Inc.
NASDAQ:IKTBiotechnology
+$0.06 today
- Market cap
- $193.57M
- Beta
- 0.97
- P/E (TTM)
- -3.4
- EPS (TTM)
- -$0.52
Volume 0.43M
Average 1.03M
IKT EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Inhibikase Therapeutics, Inc.NASDAQ: IKT
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$16.38M, compared with -$15.75M a year earlier. Trailing-twelve-month EBITDA was -$53.92M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$40.95M (+23.2%) for the fiscal year ending Dec 2026, a step up from the -93.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$16.38M-24.7% QoQ
- Last fiscal yearDec 2025
- -$53.29M-93.8% YoY
- LTMMar 2026
- -$53.92M-39.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.0% | — | — |
| 1 year | -93.8% | +23.2% | +117.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (53.29M) USD
- Year-over-year change
- -93.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (53.29M) | -93.8% |
| FY2024 | 2024-12-31 | (27.49M) | -45.8% |
| FY2023 | 2023-12-31 | (18.85M) | -4.5% |
| FY2022 | 2022-12-31 | (18.05M) | — |
| FY2021 | 2021-12-31 | 0 | — |
EBITDA vs competitors
How IKT compares with its peers on the latest reported figures
- IKT's LTM Mar 2026 EBITDA of -$53.92M is the 7th highest of the 8 companies compared; the peer median is -$12.35M.
- Its year-over-year change of -39.7% is the 5th highest of 7, against a peer median of -29.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
TTRXTurn Therapeutics Inc. | LTM Mar 2026 | -$3.79M | — | — | — |
EXOZeXoZymes, Inc. | LTM Mar 2026 | -$9.84M | -54.8% | — | — |
| LTM Mar 2026 | -$12.35M | -23.1% | — | — | |
| LTM Mar 2026 | -$19.31M | +41.5% | — | — | |
| LTM Mar 2026 | -$21.76M | -35.5% | — | — | |
| LTM Mar 2026 | -$53.92M | -39.7% | — | — | |
| LTM Mar 2026 | -$342.25M | -325.9% | — | 4567.0% | |
| Peer median (excluding IKT) | -$12.35M | -29.3% | — | 2334.8% | |
Competitors are the stored peer set for IKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.1M | 123.44K | 260.5K | 0 | 0 |
| Cost of Revenue | 11.36M | 6.72K | 13.62M | 26.27K | 0 |
| Gross Profit | (8.26M) | 116.72K | (13.36M) | (26.27K) | 0 |
| Gross Margin | -266.4% | 94.6% | -5127.8% | — | — |
| Research & Development | 11.36M | 12.03M | 13.62M | 17.21M | 29.79M |
| Selling, General & Admin | 0 | 6.21M | 6.73M | 11.38M | 23.56M |
| Operating Expenses | 6.51M | 18.25M | 6.73M | 28.56M | 51.97M |
| Depreciation & Amortization | 14.77M | 6.72K | 177.4K | 26.27K | 60.5K |
| EBITDA | 0 | (18.05M) | (18.85M) | (27.49M) | (53.29M) |
| EBITDA Margin | 0.0% | -14620.4% | -7236.7% | — | — |
| Operating Income | (14.77M) | (18.13M) | (20.09M) | (28.59M) | (51.97M) |
| Operating Margin | -476.2% | -14686.2% | -7712.0% | — | — |
| Interest Income | 19.92K | 74.45K | 1.06M | 1.07M | 3.72M |
| Interest Expense | 19.92K | 74.45K | 0 | 0 | 0 |
| Other Income / Expenses | (19.92K) | 74.45K | 1.06M | 1.07M | 3.72M |
| Income Before Tax | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Pre-Tax Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (14.79M) | (18.05M) | (19.03M) | (27.52M) | (48.26M) |
| Net Margin | -476.9% | -14625.9% | -7304.8% | — | — |
| EPS (Basic) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| EPS (Diluted) | (4.88) | (4.26) | (3.57) | (1.16) | (0.49) |
| Weighted Avg Shares | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
| Weighted Avg Shares (Diluted) | 3.03M | 4.2M | 5.33M | 69.36M | 98.31M |
Inhibikase Therapeutics, Inc.
NASDAQ:IKT
Intrinsic Alpha fair value
Locked
Current Price
$1.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.